A three-dimensional ͑3D͒ intensity-modulated radiotherapy ͑IMRT͒ pretreatment verification procedure has been developed based on the measurement of two-dimensional ͑2D͒ primary fluence profiles using an amorphous silicon flat-panel electronic portal imaging device ͑EPID͒. As described in our previous work, fluence profiles are extracted from EPID images by deconvolution with kernels that represent signal spread in the EPID due to radiation and optical scattering. The deconvolution kernels are derived using Monte Carlo simulations of dose deposition in the EPID and empirical fitting methods, for both 6 and 15 MV photon energies. In our new 3D verification technique, 2D fluence modulation profiles for each IMRT field in a treatment are used as input to a treatment planning system ͑TPS͒, which then generates 3D doses. Verification is accomplished by comparing this new EPID-based 3D dose distribution to the planned dose distribution calculated by the TPS. Thermoluminescent dosimeter ͑TLD͒ point dose measurements for an IMRT treatment of an anthropomorphic phantom were in good agreement with the EPID-based 3D doses; in contrast, the planned dose under-predicts the TLD measurement in a high-gradient region by approximately 16%. Similarly, large discrepancies between EPID-based and TPS doses were also evident in dose profiles of small fields incident on a water phantom. These results suggest that our 3D EPID-based method is effective in quantifying relevant uncertainties in the dose calculations of our TPS for IMRT treatments. For three clinical head and neck cancer IMRT treatment plans, our TPS was found to underestimate the mean EPID-based doses in the critical structures of the spinal cord and the parotids by ϳ4 Gy ͑11%-14%͒. According to radiobiological modeling calculations that were performed, such underestimates can potentially lead to clinically significant underpredictions of normal tissue complication rates.
I. INTRODUCTION
The convenience and the reasonable spatial resolution offered by modern electronic portal imaging devices ͑EPIDs͒ has stimulated considerable recent research regarding their use as two-dimensional ͑2D͒ dosimeters in intensitymodulated radiotherapy ͑IMRT͒ verification procedures. [1] [2] [3] [4] [5] [6] We recently developed a deconvolution-based method of accurately measuring 2D incident fluence distributions with an amorphous silicon flat-panel EPID. 5 The procedure formed the foundation for a clinical 2D IMRT verification technique that calculates the absolute 2D dose distribution at 10 cm depth ͑beams eye view plane͒ in a water phantom using the measured 2D incident fluence for each IMRT field. This dose distribution is then compared with the analogous distribution calculated by the treatment planning system ͑TPS͒ used for IMRT planning. The 2D verification method is designed to identify the following errors: systematic procedural errors, e.g., in the transfer of the multileaf collimator ͑MLC͒ leaf sequence files from the TPS to the record and verify system; any mechanical problems that the MLC controller may encounter in delivering the intended leaf sequence; and errors in TPS dose calculations due to both the failure of our TPS to account for the interleaf leakage and the inaccurate modeling of the commonly occurring small subfields in step-and-shoot IMRT field segments. However, one major limitation of this method is that it is not evident how the errors quantified in a 2D dose at a single depth in a water phantom relate to the cumulative errors in a three-dimensional ͑3D͒ dose distribution in the patient from all beams in the IMRT plan. This limitation makes it difficult to assess the potential clinical significance of dosimetric uncertainties: errors that appear small in the 2D dose might become additive in the 3D patient dose distribution, or vice versa, errors that appear high in a single field may not be relevant in the total 3D plan.
In the present study, we describe the development of a complementary "3D" IMRT verification technique where 3D doses are calculated. A number of researchers have investigated techniques of 3D dose reconstruction using EPID measurements of exit fluence acquired during a treatment session with the patient in the beam. [7] [8] [9] Unlike these techniques, the technique we describe is a more rudimentary pretreatment ͑i.e., no patient͒ 3D verification technique based on EPID measurements of primary fluence. A somewhat similar pretreatment verification technique, but using film, has recently been described by Renner et al. 10 In their work, for each IMRT field, a 2D dose distribution was measured using film placed below a 3 mm copper buildup plate. These 2D distributions were then used as the primary fluence input for calculations of the 3D dose employing an in-house pencil-beam superposition algorithm. The verification was a comparison of these doses to analogous doses calculated by a commercial treatment planning system.
With our technique, EPID images are acquired of each step-and-shoot IMRT field and its corresponding "open field." The open field uses the same secondary collimator settings as the IMRT field, but the MLC is retracted. IMRTfield and open-field 2D fluences are extracted from the two images using our kernel-based deconvolution technique to eliminate blurring of the fluence caused by scattering within the EPID and the water-buildup placed on its surface. The ratio of IMRT field to open-field fluences provides a 2D relative fluence modulation profile for each IMRT field. These 2D modulation profiles are then used as input to our commercial TPS, which then generates a 3D dose distribution using the patient's CT data. In this process, the interleaf leakage is included in the measured fluence. Also, since the 2D fluence modulation is measured for the entire IMRT field, the TPS is not required to model very small subfields. The verification consists of comparing this 3D dose distribution, using measured fluence modulations, to the original inverseplanned 3D dose distribution calculated by the same TPS, using TPS-optimized fluence modulations. Discrepancies between these two dose distributions are quantified and displayed along with the 3D patient anatomy. Now, unlike our 2D technique, our 3D dose differences are cumulative and arise from all the fields of an IMRT treatment. Since in our method the TPS performs the dose calculation step for both the EPID-based and the original TPS-based doses, commissioning of an independent dose algorithm is not necessary; however, only the fluence modeling step of the TPS calculations will be verified.
Our 3D technique was used to retrospectively verify three clinical head and neck cancer IMRT treatments. Relevant dose-volume statistics for specific clinical volumes of interest were generated and used as input for radiobiological modeling calculations. These calculations are useful indicators of the potential clinical impact of dosimetric uncertainties in IMRT treatments.
II. MATERIALS AND METHODS

A. Image acquisition with the aS500 EPID
The aS500 EPID ͑Varian Medical Systems, Palo Alto, CA͒, described elsewhere, 5 was used in this study. Radiation was delivered to the EPID with a Varian 2100 EX accelerator equipped with a 120-leaf Millenium MLC ͑Varian Medical Systems͒. EPID images were acquired at a source to detector distance ͑SDD͒ of 105 cm, using 100 MUs ͑unless otherwise specified͒ at a dose rate of 100 MU/ min in the IMRT mode ͑Varis Portal-Vision version 6.1, Varian Medical Systems͒. In this mode, image frames are acquired at a constant rate of 7.5 and 10.7 frames per second for 15 MV and 6 MV ͑at 100 MU/ min͒, respectively during the radiation delivery, and are automatically averaged, and subsequently dark-field and flood-field corrected. To keep the absolute pixel values proportional to the incident fluence, in this study the original EPID images were multiplied by the number of acquisition frames to create a new raw EPID image, EPID raw .
5
B. Convolution kernels: Monte Carlo model of the aS500 EPID
Because of the linearity of the aS500's dose response, [11] [12] [13] each pixel value is proportional to the optical energy incident on that pixel. The degradation of spatial resolution in the aS500 occurs due to x-ray scatter in the buildup material and phosphor screen, and to optical scattering ͑or "glare"͒ in the screen. Therefore, the 2D signal recorded by the aS500 ͑for our measurements of in-air fluences͒ is essentially a convolution of the primary photon fluence, ⌿ p ͑x , y͒, with a spreading kernel ͑Fig. 1͒. The kernel can be modeled as a convolution of two component kernels at a given photon energy E : K dose E ͑x , y͒ which accounts for the spread in dose deposition in the Gd 2 O 2 S : Tb screen, and K glare E ͑x , y͒, which characterizes the optical photon spreading from the screen to the photodiode layer. Image restoration must, therefore, be performed on the EPID images to measure the true spatial distribution of photon fluence required in IMRT verification. The 15 MV kernels K backglare 15MV ͑x , y͒ and K dose 15MVЈ ͑x , y͒ have been described in our previous work 5 ͓named K glare 15MV ͑x , y͒ and K dose 15MV ͑x , y͒, respectively͔; therefore, only the development of the 6 MV kernels will be described in this section.
For 6 MV photons, an initial pencil-beam dose-deposition kernel, K dose 6MVЈ ͑x , y͒, was generated using EGSnrcMP Monte Carlo software 14 ͑XYZDOS, within ±5% uncertainty at 2 cm distance from pencil beam axis, 3 ϫ 10 8 histories͒ to score the dose deposited in the Gd 2 O 2 S : Tb screen in Cartesian coordinates, using the approximate EPID structure depicted in Fig. 1 . The PRESTA-II algorithm and the values ECUT = 0.521 MeV ͑electron rest mass and kinetic energy͒, PCUT= 0.010 MeV, were used in our Monte Carlo simulations. Both the pencil-beam and scoring pixel dimensions ͑0.0784ϫ 0.0784 cm 2 ͒ were chosen to match the EPID pixel size. This simplified model of the aS500 EPID's structure consists of copper, Gd 2 O 2 S : Tb, and a glass substrate. As suggested in Fig. 1 , our setup includes 2 cm of waterequivalent buildup material placed on top of the EPID to provide 3 cm of buildup ͑1 cm of intrinsic EPID buildup 12 
͒.
This was required for measurements of dose at d max for the 15 MV photon beam, and provides more than adequate buildup for 6 MV photon beams. This amount of buildup was chosen to streamline the IMRT verification process, so that once set up, verification could be done for both 6 and 15 MV fields without re-entering the Linac vault. The incident 6 MV photon energy spectrum was obtained from Sheikh-Bagheri and Rogers. 15 In our previous simplified model for 15 MV photons, a 2.5-cm-thick, water-equivalent backscatter layer 16 was added beneath the glass substrate to approximate the material lying underneath the EPID structure. An empirical function containing the sum of two exponential functions was used to describe K backglare 15MV ͑x , y͒ whose coefficients were obtained by fitting to the fluence measured with a diamond detector ͑PTW Freiburg, Germany͒ for several field sizes. For the 6 MV case, however, it was determined that no amount of water-equivalent backscatter could be added that could even partially describe the backscattering properties of the EPID consistently for all field sizes. Instead, the initial dosedeposition kernel K dose 6MVЈ ͑x , y͒ was generated with no backscatter material present ͑Fig. 1͒. The kernel K backglare 6MV ͑x , y͒ representing the combined effect of the long range backscatter and the short range optical glare was obtained by fitting to the incident fluence measured by a diamond detector in open fields. The K backglare 6MV ͑x , y͒ kernel amplitude at a particular location r ͑in centimeters͒ from the incident pencil beam can be fitted by a triple-exponential function of the form
The parameters C 1 = 37.14 cm −1 , C 2 = 1.5685ϫ 10 −5 , C 3 = 0.4054 cm −1 , C 4 = 1.404ϫ 10 −6 , and C 5 = 0.015 31 cm −1 , offered the best agreement between fluence profiles measured with a diamond detector and profiles extracted ͑dis-cussed in the next section͒ from aS500 EPID images. The first term in Eq. ͑1͒ was assumed to describe the short range optical glare, and is the same as the first term derived previously for the 15 MV kernel K backglare 15MV ͑x , y͒. The second term in the 15 MV and the last two terms in the 6 MV empirical function may account for shortcomings due to the simplified model of the backscatter. Difficulties associated with the unknown and nonuniform backscatter material in the aS500 EPID have been pointed out previously. 17 The final dose-glare kernel describing the signal spread in the EPID can be expressed as
where denotes a convolution operation.
C. Flood-field normalization effect on primary fluence
EPID images are automatically flood-field corrected by the image acquisition software using a flood field image acquired during EPID calibration. Ideally, for dosimetric studies, this flood-field image should be generated using a perfectly uniform fluence incident on the EPID. However, this flood-field image is not flat, since it is generated from an open photon beam that contains the horns caused by the flattening filter. Therefore, the flood-field correction not only corrects for pixel-to-pixel sensitivity variations, as intended, but also removes the horns in the EPID image. This causes spatial distortions in the fluence distribution extracted from an EPID image. To prevent such distortions but still correct for pixel-to-pixel variations in sensitivity, we multiply EPID raw (x , y) by I flood-sim E ͑x , y͒, a pseudo-EPID flood-field image acquired at photon energy E, containing no variability in pixel sensitivity. The 2D, 6 MV flood field I flood-sim 6MV ͑x , y͒ was derived in the same manner as the 15 MV flood field, I flood-sim 15MV ͑x , y͒, described previously, 5 but using a 6 MV Linac spectrum.
D. Deconvolution of EPID raw "x , y…
For a given beam energy, the primary photon fluence ⌿ p ͑x , y͒ incident on the aS500 can therefore be determined from the raw EPID image EPID raw ͑x , y͒, the appropriate dose kernel, backscatter-glare kernel, and the pseudo-EPID floodfield image in the following manner:
͑3͒
The process of deconvolution is represented by −1 . The superscripts designating the beam energy are omitted in Eq. ͑3͒ and henceforth, in all variables. The deconvolution was performed in the spatial frequency domain using a fast Fourier transform algorithm available in MATLAB ͑The Mathworks Inc., Natick, MA͒.
E. IMRT verification using 2D beam's eye view dose distributions
Our method of calculating 2D absolute dose profiles at 10 cm depth in a water phantom using EPID-measured 2D relative primary fluence profiles has been described in detail in our previous work. 5 Briefly, the process of calculating EPIDbased doses ͑D EPID ͒ is described by the equation
͑4͒
The EPID-measured fluence for a given field, ⌿ p ͑x , y͒, is calculated using Eq. ͑3͒ and then convolved with an EGSnrcMP-derived dose-deposition kernel, K phantom , to yield a dose image ͑in arbitrary dose-pixel units͒ at 10 cm depth in a water phantom. Using the same procedure to generate dose images of a calibration field imaged with several different monitor units and by measuring the corresponding absolute point doses with an ion chamber at 10 cm depth in a water phantom, an absolute dose calibration factor, k cal , was extracted. In our previous work, good agreement between these 2D EPID-based doses and similar doses measured using film was shown. Our current clinical 2D IMRT verification method consists of a beam-by-beam comparison of these 2D EPID-based doses to the analogous doses calculated by our commercial TPS, TMS-Helax ͑Nucletron B.V., Veenendaal, The Netherlands͒. For all TPS dose calculations discussed in this work, the TPS employed a well-known pencil-beam convolution dose algorithm.
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F. IMRT verification using 3D dose distribution on a patient's CT anatomy
At our clinic, inverse-optimized, step-and-shoot IMRT treatment plans are generated using the TMS-Helax TPS. For each field in the IMRT treatment plan to be verified, two EPID raw images are acquired: a "MLC" image of the delivered step-and-shoot sequence of the IMRT field, and an image of the corresponding open-field defined solely by the secondary collimators, with these collimators located at the same positions as used for the first image. The 2D relative fluence profile for each of these images is calculated using Eq. ͑3͒. The measured 2D fluence modulation, ⌿ mod ͑x , y͒, for each IMRT field is then determined from the MLC-toopen-field ratio of the relative primary fluences
The measured ⌿ mod ͑x , y͒ from Eq. ͑5͒ for each field is resampled on a larger 0.15ϫ 0.15 cm 2 grid using linear interpolation, and then formatted appropriately for import as a "compensator" file into the TPS. In other words, the measured ⌿ mod ͑x , y͒ replaces the ⌿ mod ͑x , y͒ optimized by the TPS for each field in the IMRT plan. This process only replaces the modeling of the step-and-shoot MLC sequence for each field with a "virtual" compensator without changing the energy, the field shape and the relative weights. Using the measured ⌿ mod ͑x , y͒, the TPS is then used to recalculate the cumulative ͑i.e., all beams together͒ 3D dose distribution, D EPIDflu , with respect to the patient's CT anatomy. A type of "3D IMRT verification" is then furnished by comparing D EPIDflu to the planned dose-distribution using the TPSoptimized fluence modulations ͑designated D TPS ͒. This process of creating 3D IMRT dose distributions required for verification is illustrated in Fig. 2 .
In our TPS, individual beam dose distributions in the patient are normalized to a standard dose, defined at d max in a water phantom for a 10ϫ 10 cm 2 field size with a SSD of 100 cm. These normalized beam doses, weighted by specified beam weights, are then added together to obtain the dose distribution for the entire plan. This summed dose, denoted as the un-normalized dose prior to plan normalization, is reported by the TPS only for the specified points of interest, and not for the volumes of interest or the entire dose distribution. Subsequent plan normalization is then used to prescribe an absolute dose for this plan. For IMRT plans, it is our practice to prescribe the treatment dose to the median planning target volume ͑PTV͒ dose calculated from the unnormalized distribution. However, the median un-normalized dose ͑i.e., the dose relative to the standard dose͒ may be different due to the discrepancies between the measured and the TPS-optimized ⌿ mod ͑x , y͒. This difference is thus lost in the plan normalization and dose prescription process. In the final comparison between D EPIDflu and D TPS , we wanted to keep both the conventional IMRT plan normalization including dose prescription and the difference in the median PTV dose ͑i.e., relative to the standard dose͒. This was achieved by calculating a correction factor N corr such that D EPIDflu → N corr · D EPIDflu . The correction factor was calculated as follows. Both D EPIDflu and D TPS plans were temporarily normalized to a common normalization point, and median PTV doses, D EPIDflu,PTV and D TPS,PTV , were then calculated for this normalization. This normalization process, however, results in the loss of the difference in the absolute dose at the normalization point. The absolute dose difference was restored by recording the un-normalized EPID and TPS doses ͑i.e., relative to the standard dose͒ at the normalization point, The steps and equations required to produce an appropriate modulation matrix for each IMRT field are shown in ͑a͒. These matrices and patient CT data ͑b͒ are employed by the treatment planning system to generate 3D IMRT dose distributions.
tional to the absolute dose at the normalization point in each 3D dose distribution. Then N corr is given by the following equation:
Analysis of the verification results was performed using an in-house software ͑Fig. 3͒ tool developed in the MAT-LAB programming environment to show the 3D dose difference distribution overlaid on a patient's CT anatomy. The software also allows display of the tumor and normal tissue contours delineated previously in the TPS. Dose differences in these volumes are summarized in terms of dose-volume histograms ͑DVHs͒ and dose difference statistics. Results are reported for 3D verifications that were performed retrospectively on three clinical head-and-neck cancer IMRT treatment plans: one comprised of eight 15 MV beams, another with eight 6 MV beams, and a third with six 15 MV and two 6 MV beams.
G. TPS dose calculations with a "point-source" model
In its dose calculation algorithm, the TPS models beam penumbra by including an additional penumbra dose convolution kernel dependent on "beam-size" parameters, rather than explicitly modifying the energy fluence itself. However, EPID-measured 2D-fluences intrinsically contain all penumbral information, as proven by the very good agreement between open field fluence distributions measured with the EPID and those measured with a diamond detector. Therefore, derived fluence modulations ͑⌿ mod ͒ imported into the TPS already contain penumbral blurring at the treatment field edges. However, the TPS considers the imported ⌿ mod as a virtual compensator and applies the penumbra dose kernel at the treatment field edges to calculate the EPID-based dose ͑D EPIDflu ͒, which is unnecessary. Since the planned ⌿ mod does not contain the penumbral blurring, this problem does not exist for the D TPS dose. To quantify the significance of this effect, EPID-based dose calculations were also performed with the beam-size parameters used in the penumbra kernel reduced from ϳ0.5 to 0.001 cm, to effect a pointsource that avoids additional penumbral blurring. EPIDbased doses calculated using this point-source TPS model are designated as D EPIDflu/pnt .
H. Calculation of 2D dose profiles of D EPIDflu and comparison with D EPID
We wish to identify any errors in the 3D calculation method by taking advantage of the accuracy, even for small fields, of the 2D calculation method that we described previously. D EPIDflu dose distributions are based on the measurement of ⌿ mod , import of this modulation matrix into the TPS, and use of the TPS to perform the dose convolution. D EPID dose distributions, however, are based on measurement of ⌿ p and a dose calculation by Eq. ͑4͒ which is independent of the TPS. Both of these methods rely on EPID-measured fluences, and can be used to calculate 2D beam's eye view ͑BEV͒ dose distributions at 10 cm depth in a water phantom. Comparison of D EPIDflu and D EPID for small fields allows an assessment of the accuracy of the TPS dose calculation. A 40ϫ 40ϫ 25 cm 3 water phantom was "modeled" in the TPS for the purpose of calculating the 2D BEV dose distribution from single fields using the 3D approach. Equation secondary collimators set to 20ϫ 20 cm 2 ; a single segment of a step-and-shoot IMRT field; and the entire IMRT fields of the three treatment plans for which a 3D IMRT verification was performed. The EPID images, required to calculate D EPIDflu and D EPID , were acquired using 40 MUs/ image for the open and IMRT-segment fields, and 100 MUs/ image for the multisegment IMRT fields ͑all at 100 MU/ min͒. In order to determine the combined effects of the discrepancies between both the measured and TPS-optimized modulation matrix, and the TPS-independent and TPS-dependent dose calculations, a similar set of 2D comparisons were performed between D EPID and D TPS .
I. Comparison of 3D EPID-based doses to TLD measurements
For further validation, our 3D EPID-based verification technique was compared to an IMRT verification procedure employing thermoluminescent dosimeter ͑TLD͒ dose measurements. The latter verification had been performed as a requirement for participation in an IMRT protocol ͑RTOG H-0022͒, and involved generating and delivering an IMRT treatment plan for a hypothetical treatment of an anthropomorphic head and neck phantom. A dosimetry insert for the phantom contains regions describing primary, secondary PTVs, and a critical structure. ͑Further details of this phantom and the verification procedures can be found in Refs. 19 and 20.͒ After irradiation of the phantom, the doses recorded by the TLDs placed in each of these regions were measured by the RPC ͑Radiological Physics Center, M.D. Anderson Cancer Center, Houston, TX͒. The locations of the TLDs were also delineated on the CT scan of the phantom. The TLD doses were compared to the corresponding mean doses calculated by the TPS using the EPID-measured ⌿ mod and the TPS-optimized ⌿ mod .
III. RESULTS
A. Monte Carlo generated kernels
The Monte Carlo generated EPID initial dose kernel, empirical backscatter-glare kernel, and the combined dose-glare kernel used in restoring the 6 MV aS500 images are shown in Fig. 4 . All kernels were scored over the entire EPID phantom, which spans 30 cm. The "IMRT BEV phantom" kernel K phantom 6MV used in Eq. ͑4͒ is shown in Fig. 5 . The combined dose-glare kernels for both the 6 and the 15 MV Linac spectrums are shown in Fig. 6 . The 6 MV kernel is much narrower near the incident beamlet, however, far away, it has a much larger magnitude compared to the 15 MV kernel. This is expected, since near the beamlet the response is dominated by the range of the liberated electrons from primary interactions, and in the far-range by lateral photon scattering. The shape of these dose-glare kernels is well described by the following function, which is the sum of five exponential terms: 
B. Fluence profiles from the aS500 EPID and diamond detector scans
Cross-plane scans using 6 MV photons, for 10ϫ 10 cm mond detector with a brass buildup cap ͑1.1 cm diameter͒. It is assumed that these profiles are proportional to the incident energy fluence. The dashed lines show profiles of the raw EPID image acquired using the aS500 in IMRT mode, and the dotted lines show profiles of the EPID image corrected using Eq. ͑3͒. Compared to the diamond fluence profiles, the raw EPID profiles are much larger in the penumbral tails, rounded in the penumbra itself, and do not show the horns caused by the flattening filter. Field sizes of 2 ϫ 2 cm 2 , 4 ϫ 4 cm 2 , 10ϫ 10 cm 2 , and 20ϫ 20 cm 2 were used to determine the parameters of the backscatter-glare kernel that minimized the difference between diamond detector and deconvolved profiles in the penumbra tails. EPID corrected profiles are in excellent agreement with the diamond detector scans, including penumbra tails and edges, as well as the profile horns. The diamond energy fluence scans have a slightly smoother penumbra because of the 1.1 cm diameter brass buildup cap and the 2.2 mm ͑sensitive volume͒ diameter diamond detector.
Fluence profiles obtained from the aS500 image were also tested using small fields commonly found in IMRT segments. Figure 9 shows one segment from a clinical 6 MV IMRT field, where the dotted line indicates the location of the profile shown in Fig. 10 . For all subfields in the segment ͓ranging from 0.5 cm ͑subfield 1͒ to 2.5 cm ͑subfield 2͔͒, fluences are accurately measured using the corrected EPID image. This segment delivers a sharp, nearly constant fluence within open subfields, while the fluence drops substantially in the near-penumbra region ͑between subfields 5 and 6͒. Ideally, we would expect this type of fluence profile, where the peak heights vary only slightly due to the horn shape of an open-field fluence. Because of the buildup cap used, diamond detector profiles are not as sharp, and volumeaveraging effects cause small subfields to be underrepresented ͑subfield 1͒, and penumbra regions to be overrepresented. Raw EPID profiles have an even poorer spatial response, and severely over-represent the fluence outside of the open subfields. For the larger open field sizes-4 ϫ 4, 10ϫ 10, and 15 ϫ 15 cm 2 -there is good agreement between all methods of calculating the 2D dose in the central ROI ͑ROI1͒, for both photon energies. The mean dose differences are less than 2% in all cases, and the standard deviations are less than or equal to 0.7%. For the larger ROI ͑ROI2͒, which also includes penumbral regions, the standard deviations ranging from 1.7% to 2.9% for the D EPIDflu − D EPID comparison do suggest a non-negligible difference between the two EPID-based methods of calculating dose. These discrepancies arise from differences between our method of dose convolution and our convolution kernel and those of the TPS; and from any errors introduced in the process of importing the fluence modulation into the TPS. The standard deviations of 4.5%-5.4% for D TPS − D EPID indicate a significantly larger disagreement between the reference D EPID dose and the dose calculated by the TPS using TPS-optimized ⌿ mod . This suggests that even for these relatively large field sizes, the penumbra modeling of the TPS is less than ideal.
Differences between D TPS and the two EPID-based doses are much more pronounced for the smaller field sizes ͑2 ϫ 2, 10ϫ 1, and 1 ϫ 10 cm 2 ͒. The mean D EPIDflu dose differs from the mean D EPID dose by at most 2.4% and 0.9% in ROI1 and ROI2, respectively. In contrast, mean dose differences between D TPS and D EPID are as large as 10.6% in the central ROI and 17.4% in the larger ROI2: in ROI1, mean ͑D TPS − D EPID ͒ ranges from −3.9% to 5.9% for 6 MV and from −10.6% to 3.7% for 15 MV; in ROI2, these ranges are −16.2% to 3.0% ͑6 MV͒ and −17.4 to 3.3% ͑15 MV͒. Deficiencies in the TPS's modeling of small fields are further emphasized by the standard deviations in ROI2. These values range from 6.0% to 11.4%, much larger than the analogous values of 3.4% to 4.4% for D EPIDflu − D EPID . Noteworthy is that the apparent errors in D TPS are much worse when the narrow dimension of the field is in the direction of MLC leaf travel. For example, for the 6 MV case and ROI2, the mean dose difference and standard deviation in D TPS − D EPID are −16.2% and 11.4% for the 1 ϫ 10 cm 2 field, while only 3.0% and 6.0% for the 10ϫ 1 cm 2 field. Results for the IMRTsegment field, a relatively large field with a highly irregular shape, fall in-between those obtained for the smaller and larger open field sizes. The standard deviations of 6.3% ͑6 MV͒ and 6.0% ͑15 MV͒ for D TPS − D EPID are not as large as for the 2 ϫ 2 and 1 ϫ 10 cm 2 , but still significantly larger than the corresponding values of 3.3% and 3.9% for the
For the three smaller open field sizes and the IMRTsegment field, the standard deviation in D EPIDflu/pnt − D EPID is on average 1.2% and 0.6% lower for 6 and 15 MV, respectively, in comparison to the D EPIDflu − D EPID case. Therefore, the point-source model improves the agreement between the 2D calculations using Eq. ͑4͒ and the 3D calculation of the TPS using the measured ⌿ mod . Figure 11 illustrates the differences between the methods of calculating dose for the worst-case 1 ϫ 10 cm 
Multisegment IMRT fields
Comparisons similar to those described for open fields in Sec. III C 1 earlier are summarized in Table II for 
D. Comparison of 3D EPID doses with TLD measurements
The TLD doses ͑D TLD ͒ reported by the RPC after an inverse-planned IMRT treatment was delivered to an anthropomorphic head and neck phantom are compared to analogous D TPS and D EPIDflu doses ͑Table III͒. As indicated, there is slightly better agreement with the TLD doses for D EPIDflu than for D TPS in the low-gradient regions located in the primary and secondary PTVs, though there is substantial agreement between all three doses. However, in the high-gradient region where the TLD was placed in the simulated critical structure, the D TPS dose underpredicts the TLD-measured dose by 16%. In contrast, the D EPIDflu and D TLD doses agree within the RPC-estimated uncertainty of ±3% in the TLD doses. The results using D EPIDflu/pnt are nearly identical to those obtained using D EPIDflu .
E. 3D IMRT verification of clinical IMRT treatment plans
Results from the retrospective 3D verification of three clinical head-and-neck cancer IMRT treatment plans are summarized in Table IV . For each patient, the original dose distribution calculated by the TPS, D TPS , and the dose difference distribution, D EPIDflu − D TPS ͑or D EPIDflu/pnt − D TPS ͒, are characterized by mean and standard deviation statistics for four volumes of interest ͑VOIs͒-PTV, spinal cord, right parotid, and left parotid. The dose distributions were normalized such that the median doses in the PTV for D TPS were 74, 62, and 71 Gy for patients 1, 2, and 3, respectively. As was found for the head-and-neck phantom, TPS and EPID-based doses agree well in the PTV, with the mean dose difference of 1.4 Gy ͑averaged over the three patients͒ corresponding to a 2% difference. However, in the high-gradient regions of the critical structures, there is once again a large discrepancy: the EPID-based doses are on average 3.7 Gy ͑16%͒, 4.4 Gy ͑16%͒, and 3.6 Gy ͑12%͒ higher than the TPS doses for the spinal cord, left parotid, and right parotid, respectively. DVHs for the PTV and critical structures derived from the TPS and EPID-based dose distributions for patient 3 are compared in Fig. 12 .
F. Radiobiological significance of 3D verification results
Differential dose-volume histograms for the critical structure VOIs listed in Table IV were generated and used to calculate radiobiological estimates of normal tissue complication probabilities ͑NTCPs͒ arising from the TPS and EPID-based dose distributions. NTCP calculations employing the Lyman sigmoidal dose-response model were performed using software and methods described in Ref. 21 . Model parameter values for both the spinal cord and the parotid glands are available from the Burman et al. 22 fits to the Emami et al. 23 dose-response database; additional NTCP estimates for the parotids are possible using more recent Lyman model parameter estimates published in Eisbruch et al. 24 and Roesink et al. 25 Since large uncertainties are currently inherent in such radiobiological modeling exercises, these calculations are used only to provide insight into the potential consequences of TPS dose modeling errors.
The radiobiological predictions suggest that for these three treatment plans, the spinal cord is sufficiently spared such that the additional ϳ4 Gy predicted by the EPID-based Despite the apparent improvement in the 2D comparisons obtained with the "point-soure" model ͑Sec. III C͒, the results in Tables III, IV , and V suggest the use of D EPIDflu/pnt instead of D EPIDflu has little practical impact on the 3D verifications.
IV. DISCUSSION
The advantage of 3D IMRT verification is that dosimetric uncertainties can be quantified directly with respect to ana- tomical volumes of interest, making possible a more direct evaluation of the clinical consequence of errors in TPS calculation. By comparison, the information provided by the simpler 2D IMRT verification method is generally insufficient for such assessments. At our clinic, our beam-by-beam 2D verification identifies potential problems by the presence of large "hot" ͑or "cold"͒ regions in the 2D D EPID − D TPS dose difference map, or by mean difference and standard deviation statistics for this map that fail specified criteria ͑e.g., ജ2% and 4% for the mean difference and standard deviation, respectively͒. The 2D verification is thus effective at detecting larger errors, including procedural mistakes in the deliverye.g., incorrect transfer of MLC leaf sequence file to the linac-and planning-e.g., alignment of MLC leaf junctions with a critical structure-stages of an IMRT treatment. The 2D method is ineffective, however, in quantifying the effect of smaller errors that, though present, do not arouse concern. For example, each field of the three IMRT patient treatments "passed" the 2D verification tests, as supported by the average mean dose difference of −1.1% and standard deviation of 3.4% reported for these verifications in Table II . Nevertheless, the results in Tables IV and V indicate that these small errors may lead to considerably larger than expected cumulative dose errors of up to 20% in the critical structures. Such errors may in turn have potential clinical implications as to the acceptability of these treatments, as suggested by the NTCP analysis summarized in Table V . One potential limitation of our method of verifying the 3D dose distributions calculated by our TPS is that the calculation of our EPID-based 3D doses ͑D EPIDflu ͒ relies on the TPS itself to perform the convolution step of the dose calculation. Thus, errors introduced in this step by the TPS will not be identified by our verification procedure. However, the good agreement between TLD ͑D TLD ͒ and EPID-based doses, and the large discrepancy between either of these measurement-based doses and the TPS dose in a high gradient region ͑see Table III͒, suggest that a large portion of the dose calculation errors of our TPS are introduced prior to the convolution step, e.g., in the fluence modelling stage of the calculations.
In its current implementation, our 3D method is hampered by the excessive time required to perform the verification. Although the time necessary for acquisition of the required EPID images is not long ͑ϳ1/2 hr͒, the process of converting the EPID-based fluence modulation matrices to the appropriate "compensator" file format, and particularly the actual import of these compensator files on a beam-by-beam basis into the TPS is time consuming and tedious. It is an- ticipated that the 3D method could be streamlined considerably on a TPS with a "script-based" user interface.
V. CONCLUSION
As an extension of our previously described 2D method, we have developed a 3D IMRT verification procedure based on measurement of 2D fluence modulation profiles using a flat-panel EPID. Monte Carlo simulations and empirical methods are used to derive deconvolution kernels that produce excellent agreement between EPID and diamond detector fluence profiles for both 6 and 15 MV beam energies. In our method, 3D doses are calculated using the EPID fluences and TPS-dependent convolution. 2D dose profiles in a water phantom and point doses in an anthropomorphic head and neck phantom were utilized to compare these 3D doses to analogous doses based on measurement ͑and completely TPS independent͒ and those calculated by the TPS ͑and completely measurement independent͒. These comparisons confirmed the effectiveness of our 3D EPID-based doses in quantifying uncertainties in the IMRT dose distributions calculated by the TPS. The 3D verification of three clinical IMRT treatment plans suggested that the TPS underestimated the mean doses in the critical structures of the spinal cord and the parotids by ϳ4 Gy ͑11%-14%͒. Radiobiological modeling predictions suggest that such underestimates may be clinically significant. Thus, if the method can be streamlined sufficiently, 3D verification may be a clinically useful quality assurance tool that provides information not easily accessible using more conventional 2D verification methods.
ACKNOWLEDGMENTS
This research was supported by Alberta Cancer Board Pilot Grant No. R-484. B.W. has also received support in the form of studentships from the Alberta Heritage Foundation for Medical Research and the Alberta Cancer Board, and a Dissertation Fellowship from the University of Alberta. In addition, the authors would like to thank Colin Field for his expert assistance with the TMS-Helax TPS, particularly his help in generating the point-source TPS calculations. 
